We are leading the science behind type 2 inflammation with a first-in-class treatment and robust pipeline of potential new medicines for chronic dermatological and respiratory diseases. Our research of diseases driven by type 2 inflammation is a major area of focus and investment for us and one in which we’ve already made a significant impact on the lives of patients.
In collaboration with Regeneron, we have the first and only biologic treatment approved for moderate-to-severe atopic dermatitis for adults, adolescents and children (6-11 years of age). Our treatment is also approved for adults and adolescents with moderate-to-severe asthma and adults with moderate-to-severe chronic rhinosinusitis with nasal polyps (CRSwNP). We are currently studying our treatment for use in additional type 2 inflammatory diseases including:
- allergic fungal rhinosinusitis
- bullous pemphigoid
- chronic inducible urticaria (cold urticaria)
- chronic obstructive pulmonary disorder
- chronic spontaneous urticaria
- eosinophilic esophagitis
- pediatric asthma
- prurigo nodularis
- type 2 chronic sinusitis without nasal polyposis
Above from left to right: Elizabeth, atopic dermatitis, United States; Miwako, atopic dermatitis, Japan; Jeff, asthma, Canada
- We develop a wide variety of educational materials, both in print and online, for patients and their families as well as health care professionals.
- Our Patient Advocacy group is deeply involved in the patient community, working to understand and advocate for their needs.
- Our Medical Information team is dedicated to answering questions about the diseases we treat and our products.
Learn about treatment options:
The Next Breath is for everyone with a role to play in building a brighter future for people living with severe asthma. The interactive global platform aims to bring more awareness to severe asthma, illuminate the latest science and empower people to take action to strive towards better asthma control. On The Next Breath blog you’ll find videos from real patients around the world, interviews with leading specialists and tools to help patients better understand their disease.